Agios Pharmaceuticals (AGIO) Could Be 24% Undervalued On PYRUKYND Growth Hopes

Agios Pharmaceuticals (AGIO) has drawn investor focus after recent trading left the stock at a last close of $33.63. With mixed return figures across different periods, the company’s rare disease portfolio is gaining fresh attention.

See our latest analysis for Agios Pharmaceuticals.

Over the past year, Agios Pharmaceuticals has combined a 23.73% year to date share price return with a 21.28% 90 day share price gain, yet the 1 year total shareholder return declined 10.20%. This suggests that recent momentum follows a weaker longer term experience.

If you are reassessing risk and opportunity after Agios Pharmaceuticals' recent moves, it can be useful to broaden your watchlist with other healthcare focused ideas such as 40 healthcare AI stocks

Agios Pharmaceuticals now trades well below both one measure of intrinsic value and the average analyst target after its recent rebound. Is this simply market caution around ongoing losses, or a mispriced rare disease opportunity that could be clarified by further valuation work?

Most Popular Narrative: 23.6% Undervalued

At a last close of $33.63 versus a narrative fair value of $44.00, Agios Pharmaceuticals is framed as undervalued, with that gap hinging on how its rare disease portfolio converts into future cash flows.

Upcoming potential FDA approval and commercial launch of PYRUKYND for thalassemia in the U.S. is set to significantly expand Agios' addressable market. This is driven by the high rate of disease diagnosis through newborn screening and well-defined patient populations, which the narrative suggests could lift revenue growth in coming years.

Read the complete narrative.

Want to see what underpins that fair value jump for Agios Pharmaceuticals? The narrative leans on rapid revenue build, margin repair, and a rich future earnings multiple. Curious how those ingredients combine into a $44.00 valuation.

Result: Fair Value of $44.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Agios Pharmaceuticals story still leans heavily on PYRUKYND execution and carries ongoing spending and safety risks that could quickly challenge this undervalued narrative.

Find out about the key risks to this Agios Pharmaceuticals narrative.

Another View on Agios Pharmaceuticals Valuation

The first fair value view presents Agios Pharmaceuticals as significantly undervalued. However, when using the P/S ratio, the picture looks far more demanding. Agios trades at 20.4x sales, compared with 10.9x for the US Biotechs industry and a fair ratio estimate of just 0.2x. That spread implies considerable execution risk if growth or margins fall short. How comfortable are you with paying that kind of premium for an unprofitable stock?

For a closer look at how these sales based signals compare with fundamentals, it is worth reviewing the detailed valuation breakdown, including where the ratio could move if sentiment changes, in the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment split between opportunity and risk around Agios Pharmaceuticals, it makes sense to move quickly and review the underlying data for yourself. To balance both the upside potential and the concerns raised by the market, take a closer look at the 2 key rewards and 1 important warning sign

Looking for more investment ideas beyond Agios Pharmaceuticals?

If Agios Pharmaceuticals has sharpened your focus on where risk and reward meet, do not stop here. Fresh ideas often come from comparing a few very different stocks.

• Supercharge your hunt for potential bargains by scanning companies highlighted in the 53 high quality undervalued stocks
• Prioritize resilience and sleep easier at night by checking out businesses flagged in the 80 resilient stocks with low risk scores
• Target stronger balance sheets and fundamentals by reviewing opportunities surfaced in the solid balance sheet and fundamentals stocks screener (50 results)

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com